Stock REGN34 REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Regeneron Pharmaceuticals, Inc. Sao Paulo

Equities

REGN34

BRREGNBDR005

Market Closed - Sao Paulo
Other stock markets
 10:57:17 2024-07-02 EDT 		5-day change 1st Jan Change
98.11 BRL -1.40% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.67% +44.05%
10:25am Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval MT
07:45am Sanofi obtains EU approval for Dupixent RE

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit
Sanofi obteint l'approbation de L'UE pour le Dupixent
Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie
EU approves Sanofi's Dupixent for 'smoker's lungs'
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
ETF de la semana: Invertir en Europa fuera de Francia para evitar el riesgo político
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
FDA approves Verona Pharma's therapy for 'smoker's lungs'
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia
Compañías que se deben tener muy en cuenta por técnico este martes en Wall Street
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. REGN34 Stock
  5. News Regeneron Pharmaceuticals, Inc.
  6. Other languages